我们都在努力寻找COVID-19的治疗药物,这也在考验美国快速开发、检测以及部署药物治疗的能力,这对于我们的药物评估体系是机遇也是挑战。这次美国应对疫情在数个方面的表现非常令人担忧,凸显了在发生公共卫生危机时,我们药物审评体系将如何出现问题。
这次全球性的病毒大流行给临床医师以及美国食品药品管理局(FDA)施加了巨大压力,希望其迅速找到治疗患者的药物。因此当非常有限的来源于观察性的个别证据显示治疗疟疾的药物——氯喹以及羟氯喹可能对于SARS-CoV-2病毒有效的时候,特朗普总统就迫不及待地开始庆祝,宣称它们可以被广泛用于本次大流行,并在电视上宣布,他的“直觉”告诉他这些药物很有效,其会成为这次大流行扭转局面的决定因素。最近,他还公开鼓励患者服用这些药物,并暗示他也会服用该药,尽管他并未感染SARS-CoV-2。
作者信息
Benjamin N. Rome, M.D., and Jerry Avorn, M.D.
From the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston.
参考文献
1. Kim AHJ, Sparks JA, Liew JW, et al. A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19. Ann Intern Med 2020 March 30 (Epub ahead of print).
2. Pavia AT. Editorial commentary: what did we learn from the emergency use authorization of peramivir in 2009? Clin Infect Dis 2012;55:16-18.
3. Downing NS, Aminawung JA, Shah ND, Braunstein JB, Krumholz HM, Ross JS. Regulatory review of novel therapeutics — comparison of three regulatory agencies. N Engl J Med 2012;366:2284-2293.
4. Darrow JJ, Avorn J, Kesselheim AS. FDA approval and regulation of pharmaceuticals, 1983-2018. JAMA 2020;323:164-176.
5. Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020;382:1787-1799.